The potential of KRAS inhibitors for non-small-cell lung cancer

Share :
Published: 22 Apr 2020
Views: 2158
Prof Reinhard Büttner - University Hospital Cologne, Cologne, Germany

Prof Reinhard Büttner speaks to ecancer about a pathologist's perspective on targeting KRAS-driven oncogenic signalling in non-small-cell lung cancer (NSCLC). This discussion covers developments that were due to be presented at the ELCC conference, which was cancelled due to the COVID-19 pandemic.

Prof Büttner outlines how KRAS mutations offer a promising option for targeted therapies in NSCLC in certain populations.

He explains that, from a diagnostic point of view, KRAS mutations are straightforward to identify. However, KRAS inhibitors have previously been considered too toxic clinically.

From his perspective as a pathologist, Prof Büttner comments on the significance of genomic testing and personalised medicine in lung cancer treatment.

Prof Büttner concludes by saying that new drugs like AMG 510, a KRAS G12C inhibitor, offer a new wave of innovation for the treatment of NSCLC and significantly improved outcomes for patients. He also discusses the potential of KRAS G12C inhibitors in colon and pancreatic cancers.

This programme has been supported by an unrestricted educational grant from Bristol Myers Squibb.